BUY Aurobindo Pharma — Rakesh Bansal, 21 Sept 2026

byRakesh BansalHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via CNBC Awaaz.

Entry₹1,734.5Inferred

Target₹1,790

Stop loss₹1,700-1.99% risk

Exit₹1,70022 Sept 2026, 9:30 am

Stop-loss hit-1.99%

Follow Rakesh Bansal for new calls(32% target hit, 87 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Swing call on AUROPHARMA See 182 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 9:11 pm IST

9 supporting1 opposing

Supports the BUY call (9)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Sept · yesterday

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 5d ago

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 6d ago

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 6d ago

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 6d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.